Avalo Therapeutics, Inc. (AVTX) Dividend History

Company News

• Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

  Avalo Therapeutics announced progress in its Phase 2 LOTUS trial for hidradenitis suppurativa, with topline data expected in 2026. The company has sufficient cash runway into 2027, with potential to extend into 2028. Avalo is carefully evaluating the timing of additional development activities to preserve capital.

  GlobeNewswire Inc.
• Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

  Avalo Therapeutics, a clinical-stage biotechnology company, has appointed Jennifer Riley as its new Chief Strategy Officer. Riley brings extensive experience in the biotechnology and pharmaceutical industries, and will oversee corporate strategy, commercial and product pipeline planning to drive growth and innovation at Avalo.

  GlobeNewswire Inc.
• Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

  Avalo Therapeutics received $69.4 million in proceeds from the full exercise of warrants issued in a March 2024 private placement, bringing the total gross proceeds from the transaction to $185 million. The company plans to use the funds to expand its AVTX-009 program into additional inflammatory indications.

  GlobeNewswire Inc.
• Avalo Therapeutics to Present at Upcoming Investor Conferences

  Avalo Therapeutics, a clinical-stage biotechnology company, announced that its CEO and Chairman will present at two upcoming investor conferences in November and December 2024.

  GlobeNewswire Inc.
• Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire

  Avalo Therapeutics announced the appointment of Mittie Doyle, MD, FACR as its new Chief Medical Officer. Dr. Doyle brings over 20 years of experience in the pharmaceutical/biotech industry and will lead the development of Avalo's lead asset, AVTX-009, for the treatment of inflammatory diseases such as hidradenitis suppurativa.

  GlobeNewswire Inc.

  Featured Companies: LLY